@article{53582517a2ab47f3ba3a86f78436384e,
title = "Brentuximab Vedotin Administered To Platinum-Refractory Transplant Na{\"i}ve Hodgkin Lymphoma Patients Can Increase The Proportion Achieving FDG-PET Negative Status",
author = "Leona Holmberg and Shustov, \{Andrei R.\} and Karen Schiavo and Mary Philip and Libby, \{Edward N.\} and Cassaday, \{Ryan D.\} and Pagel, \{John M.\} and Maloney, \{David G.\} and Green, \{Damian J.\} and Till, \{Brian G.\} and Press, \{Oliver W.\} and Gopal, \{Ajay K.\}",
note = "Background Classical Hodgkin lymphoma (HL) is characterized by CD30-positive Reed-Sternberg cells and is frequently curable with initial therapy. The standard treatment for relapsed or refractory HL is multi-agent salvage chemotherapy, most commonly with platinum-based regimens followed by high dose chemoradiotherapy and autologous stem cell transplantation (ASCT) in patients with chemosensitive disease.",
year = "2013",
month = nov,
day = "15",
language = "American English",
volume = "122",
journal = "Blood",
}